These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37330963)

  • 1. Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Ding Q; Liu Y; Ju H; Song H; Xiao Y; Liu X; Ren G; Wei D
    Med Oral Patol Oral Cir Bucal; 2023 Nov; 28(6):e525-e529. PubMed ID: 37330963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
    Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
    J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study.
    He X; Fang J; Yu P; Hu W; Zhang Q; Zhang Z; Zhou M; Wang X; Bian X
    J Thorac Dis; 2023 Dec; 15(12):6687-6696. PubMed ID: 38249866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China.
    Qu W; Wang F; Qin S; Sun Y; Huang C
    Ther Adv Med Oncol; 2024; 16():17588359241242607. PubMed ID: 38606164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.
    Yin L; Liu KC; Lv WF; Xu SB; Lu D; Zhou CZ; Cheng DL; Gao ZG; Shi CS; Su MX
    Drug Des Devel Ther; 2022; 16():3421-3429. PubMed ID: 36203820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
    Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
    Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient.
    Lin Y; Lin Y; Zhong X; Chen Q; Tang S; Chen J
    Front Oncol; 2023; 13():1280208. PubMed ID: 38090483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal alar metastasis of advanced hepatocellular carcinoma misdiagnosed as reactive cutaneous capillary endothelial proliferation in a patient treated with camrelizumab and apatinib: a case report.
    Liu J; Cao G; Zhang G; Liu S; Shi D
    J Gastrointest Oncol; 2023 Jun; 14(3):1643-1649. PubMed ID: 37435210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.
    Hua Y; Huang X; Li C; Gao N
    Oral Oncol; 2023 May; 140():106369. PubMed ID: 36989963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.
    Song G; Zhang FF; Cheng HD
    Australas J Dermatol; 2022 May; 63(2):217-221. PubMed ID: 35229882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma.
    Ma R; Wang JL; Wang YY
    Exp Hematol Oncol; 2022 Oct; 11(1):78. PubMed ID: 36289520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports.
    Hui-Mei P; Guang-Ming H; Xiao-Ling Q; Hong-Liang Z; Si-Jun W
    Indian J Dermatol; 2023; 68(3):318-326. PubMed ID: 37529461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma.
    Ju H; Wei D; Wu Y; Liu Y; Ding Q; Rui M; Fan Z; Yao Y; Hu J; Ren G
    MedComm (2020); 2023 Aug; 4(4):e312. PubMed ID: 37492783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
    Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
    Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
    Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-world Data Study of the Efficacy and Toxicity of Nivolumab
    Macia-Rivas L; Fernandez-Laguna CL; Alvarez-Asteinza C; Maray I; Carbajales-Alvarez M; Lozano-Blazquez A
    Anticancer Res; 2023 Apr; 43(4):1681-1688. PubMed ID: 36974777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
    Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
    BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
    Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
    Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.